Scholars Central

Conference abstractPublished 10 Aug 2015

Title:Bioequivalence comparison between two different formulations of alverine citrate 120mg capsules: an open label, balanced, randomized-sequence, single-dose, two-period crossover study in healthy male volunteers

Authors: Raghunadha Reddy Seelam a, I.Sarath Chandiranc, Ravindra Reddy Sd, Seelam Sai Satyanaraya Reddyd

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

An open-labeled, balanced, single-dose, 2-treatment, 2-period, 2-sequence, randomized crossover study was designed and conducted to determine the pharmacokinetic, bioavailability and bioequivalence of alverine citrate 120 mg capsules in comparison with Spasmonal Forte® 120 mg capsules after single dose administration under fasting conditions in 12 healthy adult male subjects. Each volunteer received a 120 mg capsule of the reference(or)test drug respectively. On the day of dosing, blood samples were collected before dosing & at various time points up to 4 days after dosing. Analysis of alverine and its metabolite 4-hydroxy alverine concentrations was performed using a validated LC-MS/MS method. The pharmacokinetic parameters were analyzed using the non-compartmental model. The primary pharmacokinetic parameters at 90% CI were within the 80 to 125% interval required for bioequivalence as stipulated in the current regulations of the EU acceptance criteria. The geometric mean ratios (Test/Reference) between the two products of alverine capsule under fasting condition were 111.15% (98.67%-122.4%) and 113.41% (94.68%-118.74%) for Cmax ratios, 112.72% (91.12-114.35%) and 104.54% (94.73%-103.85%) for AUC0-t ratios and 103.73% (94.45%-111.5%) and 104.56% (103.24%-107.58%) for AUC0-inf ratios of aiverine and its metabolite respectively. 12 volunteers had completed both treatments. There was no significant difference of the Tmax parameter between the two formulations (p >0.05). Drug safety and tolerability were assessed. No serious adverse events related to the study drugs were found. This single dose study found that the test formulation alverine citrate capsules is bioequivalent to the reference formulation Spasmonal Forte® capsules of 120 mg under fasting condition in healthy adult male volunteers according to the EU regulatory guidance.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Pharmaceutical Care & Health Systems.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmaceutical Care & Health Systems
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “I.Sarath Chandiranc”
  • BylineArticles whose byline prints “Ravindra Reddy Sd”
  • BylineArticles whose byline prints “Seelam Sai Satyanaraya Reddyd”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels